Peak Sales Potential For This ENT-Focused Stock Is Under-Appreciated, Says Cantor

  • Cantor initiated coverage on Lyra Therapeutics Inc LYRA with an Overweight rating and a price target of $15 (166% upside). 
  • According to the analyst, Lyra product pipeline's peak sales potential is under-appreciated, and it expects upward earnings estimate revisions to potentially move LYRA's stock higher.
  • LYRA is well-positioned with a portfolio of products to treat chronic rhinosinusitis (CRS) patients, who are both surgically-naïve with LYR-210 and post-surgical with LYR-220, to take share in the estimated $6 billion target addressable market for CRS in the U.S. 
  • LYRA has a cash runway into mid-2024 with almost $135 million cash balance.
  • Cantor believes LYR-210 enables sustained drug delivery at difficult-to-access nasal inflammation sites and avoids the systemic side effects of oral steroids. 
  • LYR-210 can be administered in a non-invasive procedure by an ENT physician serving as an alternative to invasive and costly surgery.
  • Additionally, a wide range of prices for existing CRS treatments, from $3,000 to 14,000 annually, offers flexibility to overcome competitive challenges. 
  • Price Action: LYRA shares are down 6.00% at $5.64 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsHealth CarePrice TargetInitiationAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!